Nivolumab May Induce Promising Efficacy Outcomes in Certain Gynecologic Malignancies
Immunotherapy could replace chemotherapy in some patients with recurrent/metastatic cervical and vaginal or vulvar cancers.
Abstract OBJECTIVE: To explore whether patient-reported lymphedema-related symptoms, as measured by the Gynecologic Cancer Lymphedema Questionnaire (GCLQ), are associated with a patient-reported diagnosis of lymphedema of the lower extremity (LLE) and limb volume change (LVC) in patients who have undergone radical surgery, including lymphadenectomy, for endometrial, cervical, or vulvar cancer on Gynecologic Oncology Group (GOG) study 244. METHODS: Patients completed the baseline and at least one post-surgery GCLQ and LVC assessment. The 20-item GCLQ measures seven symptom clusters-aching, heaviness, infection...
CONCLUSION: This study enforced an analysis of research trends on gynecologic malignancies in North Korean and South Korea medical journals, and a distinct difference was observed in this regard. In the future, grand scale cohort study in the genetic identical two Korean population is needed for research of environmental effect on gynecologic cancer. PMID: 31554378 [PubMed - in process]
In this study, survivors of endometrial, cervical, vaginal, and vulvar cancer who presented to the gynecologic oncology practice were asked to self-administer the Female Sexual Function Index (FSFI) survey to evaluate their sexual function. The prevalence of SD was estimated and its association with demographic and clinical co-variates was analyzed. Of the 155 participants, the prevalence of SD was 44.5% (95%CI: 36.7–52.7). Patients were significantly more likely to report SD if they did not currently have a partner (69% vs 22% p
Conclusions: A second pathology review also adds valid information in those cases with minor discrepancies leading to a difference in patients´ counselling regarding follow-up and prognosis. PMID: 31281426 [PubMed]
CONCLUSIONS: SLN mapping in endometrial and cervical cancer can easily be performed with a high detection rate by integrating ICG/NIR into a conventional laparoscopic system. Precision medicine in patients evaluated by SLN biopsy changes the way patients with endometrial or cervical cancer are managed. PMID: 31280507 [PubMed - in process]
ConclusionPelvic exenteration is a procedure that provides substantial progression-free survival and overall survival improvement and —in selected patients—can even achieve cure in otherwise hopeless clinical situations. Patients need to be offered earnest counseling for sufficient informed consent with realistic expectations what to expect.
There is a vaccine that can prevent persistent infection with the human papillomavirus (HPV), the etiological agent in many HPV-related cancers worldwide and within the United States. Globally, approximately 570,000 females and 60,000 males are diagnosed annually with a cancer that is related to the HPV.1 More than 90% of all cases of cervical and anal cancers are caused by persistent infection with the HPV, and it causes 75% of all cases of vaginal cancer, 70% of all cases of oropharyngeal and vulvar cancer, and 60% of penile cancer.
Authors: Ferreira H, Smith AV, Wattiez A Abstract The present review aims to analyze the current data available on the different applications of indocyanine green (ICG) in gynecology. A semantic review of English-language publications was performed by searching for MeSH terms and keywords in the PubMed and Google Scholar databases. The studies were finally selected by one author according to the aim of this review. ICG is a highly water-soluble tricarbocyanine dye that fluoresces in the NIR spectrum. Approved by the FDA in 1959, it can be administered either IV (usual dose of 5 mg) or locally/submucosally (usual do...
More than 90,000 gynecologic cancers are diagnosed annually in the United States, with ∼30,000 deaths every year. Cervical, ovarian, uterine, vaginal, and vulvar cancers represent the vast majority of cases, with Uterine cancer being the fourth highest incident cancer and Ovarian cancer being the eighth most common cancer diagnosed among women. Molecular landscapes of gynecologic ca ncers have recently been investigated by comprehensive studies using TCGA datasets to better understand the impact for diagnosis and treatment.
Human papillomavirus (HPV) causes cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer and oropharyngeal cancer. SCC in the genital region in particular is recognized to be caused by HPV infection, and intraepithelial lesions of the penis and vulva are termed penile intraepithelial neoplasia (PIN) and vulvar intraepithelial neoplasia (VIN), respectively. Although SCC of the nail apparatus is recognized as being associated with high-risk HPVs, it is not well-known in general medicine, and its analysis has been insufficient.